Recent Updates
Recently added Catalysts
CBIO Positive Sentiment Score: 75/100

Crescent Biopharma to Present at May Investor Conferences

Key Takeaway: Crescent Biopharma, a clinical-stage biotechnology company, announced its participation in several investor conferences throughout May 2026. The presentations include a fireside chat at the BofA Securities Healthcare Conference and other virtual events. The company aims to showcase its innovative cancer therapies, including a PD-1 x VEGF bispecific antibody.

Market Sentiment Analysis

POSITIVE FACTORS

  • Crescent Biopharma is actively engaging with investors.
  • The company is advancing innovative therapies for cancer.
  • Management is presenting at multiple prominent conferences.

Full Press Release Details

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) --Crescent Biopharma, Inc.(“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:
• BofA Securities 2026 Healthcare Conference,fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
• 2026 Stifel Virtual Targeted Oncology Forum,virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
• TD Cowen 7thAnnual Oncology Innovation Summit: Insights for ASCO & EHA,virtual fireside chat on Tuesday, May 26, 2026 at 11:30 a.m. ET
A live webcast of each presentation will be available in the Investors section of Crescent's website athttps://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.About Crescent BiopharmaCrescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visitwww.crescentbiopharma.comand follow the Company onLinkedInandX.

ContactsInvestorsAmy ReillyChief Communications Officeramy.reilly@crescentbiopharma.com617-465-0586

Frequently Asked Questions

When is Crescent Biopharma presenting at investor conferences?

Crescent Biopharma will present at several conferences in May 2026, including on May 13, 20, and 26.

What is the focus of Crescent Biopharma's presentations?

The presentations will focus on the company's innovative cancer therapies and clinical-stage pipeline.

Where can I watch Crescent Biopharma's presentations?

Live webcasts of the presentations will be available on Crescent's investor website.

What types of therapies is Crescent Biopharma developing?

Crescent is developing PD-1 x VEGF bispecific antibodies and novel antibody-drug conjugates.

Last updated: May 6, 2026